TENX
HEALTHCARETenax Therapeutics Inc
$12.02-0.47 (-3.76%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving TENX Today?
No stock-specific AI insight has been generated for TENX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$5.34$18.38
$12.02
Fundamentals
Market Cap$310M
P/E Ratio—
EPS$-1.34
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin—
Debt / Equity—
Trading
Volume1.1M
Avg Volume (10D)—
Shares Outstanding25.8M
TENX News
20 articles- Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·May 8, 2026
- Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial OfficerYahoo Finance·May 4, 2026
- Companies Like Tenax Therapeutics (NASDAQ:TENX) Are In A Position To Invest In GrowthYahoo Finance·Apr 22, 2026
- Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial OfficerYahoo Finance·Apr 22, 2026
- DraftKings, Eli Lilly downgraded: Wall Street's top analyst callsYahoo Finance·Mar 17, 2026
- Tenax Therapeutics: Q4 Earnings SnapshotYahoo Finance·Mar 10, 2026
- Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Mar 10, 2026
- Tenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare ConferenceYahoo Finance·Mar 3, 2026
- Tenax Therapeutics Shares Phase III Levosimendan Progress, H2 Data Timeline at Guggenheim ConferenceMarketbeat·Feb 15, 2026
- Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026Yahoo Finance·Feb 4, 2026
- Guggenheim Doubles Tenax (TENX) PT, Names Stock Top PickYahoo Finance·Jan 8, 2026
- Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size AssessmentYahoo Finance·Dec 17, 2025
- Tenax Therapeutics to Participate in Upcoming Investor ConferencesYahoo Finance·Nov 25, 2025
- Tenax Therapeutics: Q3 Earnings SnapshotYahoo Finance·Nov 12, 2025
- Tenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Nov 12, 2025
- Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEFYahoo Finance·Nov 6, 2025
- Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation ConferenceYahoo Finance·Nov 3, 2025
- Tenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEFYahoo Finance·Sep 16, 2025
- Tenax Therapeutics to Participate in the Cantor Global Healthcare Conference 2025Yahoo Finance·Aug 28, 2025
- Tenax Therapeutics: Q2 Earnings SnapshotYahoo Finance·Aug 13, 2025
All 20 articles loaded
Price Data
Open$12.54
Previous Close$12.49
Day High$12.77
Day Low$11.99
52 Week High$18.38
52 Week Low$5.34
52-Week Range
$5.34$18.38
$12.02
Fundamentals
Market Cap$310M
P/E Ratio—
EPS$-1.34
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin—
Debt / Equity—
Trading
Volume1.1M
Avg Volume (10D)—
Shares Outstanding25.8M
About Tenax Therapeutics Inc
Tenax Therapeutics, Inc., a specialty pharmaceutical company, is dedicated to identifying, developing, and marketing products for cardiovascular and pulmonary disease in the United States and Canada. The company is headquartered in Morrisville, North Carolina.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—